|By PR Newswire||
|April 9, 2014 06:56 PM EDT||
EMERYVILLE, Calif., April 9, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Adamas), a specialty pharmaceutical company, today announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol "ADMS" on April 10, 2014. In addition, Adamas has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock from Adamas at the initial public offering price to cover over-allotments, if any. The offering is expected to close on April 15, 2014, subject to customary closing conditions.
Credit Suisse and Piper Jaffray are acting as joint book-running managers for the proposed offering. William Blair and Needham & Company are acting as co-managers.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on April 9, 2014.
The offering is being made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus relating to these securities may be obtained, when available, from Credit Suisse Securities (USA) LLC, by mail at Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by telephone at +1 (800) 221-1037, or by e-mail at [email protected], or Piper Jaffray & Co., by mail at 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, or by telephone at +1 (800) 747-3924, or by e-mail at [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. Adamas achieves this by enhancing the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing its lead wholly owned product candidate, ADS-5102, for a complication of Parkinson's disease known as levodopa induced dyskinesia and as a treatment for chronic behavioral symptoms associated with traumatic brain injury.
SOURCE Adamas Pharmaceuticals, Inc.
Sep. 30, 2016 12:45 AM EDT Reads: 2,971
Sep. 30, 2016 12:00 AM EDT Reads: 1,672
Sep. 30, 2016 12:00 AM EDT Reads: 2,371
Sep. 29, 2016 11:30 PM EDT Reads: 1,207
Sep. 29, 2016 10:30 PM EDT Reads: 4,051
Sep. 29, 2016 10:15 PM EDT Reads: 2,794
Sep. 29, 2016 10:00 PM EDT Reads: 1,810
Sep. 29, 2016 09:45 PM EDT Reads: 3,137
Sep. 29, 2016 08:45 PM EDT Reads: 2,219
Sep. 29, 2016 08:45 PM EDT Reads: 1,551
Sep. 29, 2016 06:15 PM EDT Reads: 3,711
Sep. 29, 2016 06:00 PM EDT Reads: 1,544
Sep. 29, 2016 05:15 PM EDT Reads: 1,585
Sep. 29, 2016 05:15 PM EDT Reads: 2,861
SYS-CON Events has announced today that Roger Strukhoff has been named conference chair of Cloud Expo and @ThingsExpo 2016 Silicon Valley. The 19th Cloud Expo and 6th @ThingsExpo will take place on November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. "The Internet of Things brings trillions of dollars of opportunity to developers and enterprise IT, no matter how you measure it," stated Roger Strukhoff. "More importantly, it leverages the power of devices and the Interne...
Sep. 29, 2016 04:45 PM EDT Reads: 3,463